Why the study?
With increasing life expectancy, cognitive impairment caused by cerebrovascular diseases is growing, prompting intense discussion regarding blood pressure control to achieve optimal brain perfusion and prevent cognitive impairment.
Does antihypertensive therapy and neuroprotective treatment prevent or improve cognitive impairment in patients with hypertension?
Does antihypertensive therapy and neuroprotective treatment prevent or improve cognitive impairment in patients with hypertension?
Hypertension is a major modifiable risk factor for cognitive impairment, and blood pressure control is essential for its prevention and management.
Supports BP control in hypertension to mitigate cognitive risk; leaves open confirmation in prospective randomized trials.
As the life expectancy of the population increases, cognitive impairment (CI) caused by cerebrovascular diseases is becoming an increasingly urgent problem. The leading role of hypertension in the development of CI of various origins has led to intense discussions about blood pressure control as a potential therapeutic strategy for achieving optimal brain perfusion and about the prevention of mild and moderate CI. Hypertension is the main modifiable risk factor for stroke and cerebral small vessel damage that results in nonstroke-related CI. Antihypertensive therapy plays an essential role in preventing the development and slowing down the progression of CI through blood pressure control. Neurometabolic and neuroprotective drugs (Vinpotropil ® , Cholitilin ® ) are actively used to treat CI that does not reach the degree of dementia. When dementia develops, reversible NMDA receptor inhibitors (memantine) and central acetylcholinesterase inhibitors are used to correct CI.
No takes yet. Share an insight, caveat, or question.
Starchina et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: